DHPA joined with 215 advocacy groups to voice concern about Medicare Part B proposals outlined in President Trump’s Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs and corresponding Request for Information (RFI) that could have harmful consequences for patients with serious diseases. In a letter to HHS Secretary Alex Azar, the groups wrote, “As […]
Protecting Patient Access to Integrated GI Care in the Independent Setting
In an age when quality of care, cost-effectiveness and transparency are more important than ever, data demonstrates that high-quality, integrated care delivered in the independent medical practice setting is worthy of protection as an alternative to care that is often more costly when furnished in the hospital setting.
DHPA strongly supports the Medicare Care Coordination Improvement Act of 2017 (H.R. 4206, S. 2051), which promotes care coordination and will enable physicians to participate more fully in the value-based payment models incentivized by the bipartisan Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) (Pub. L. 114-10, enacted April 16, 2015). H.R. 4206, was […]
Published in American Journal of Managed Care As physicians, the health of our patients is always our first consideration. But unfortunately, patients aren’t always permitted to benefit from the treatment plan that physicians prescribe. Some patients are forced to try one or more medications that end up not helping them before insurers will allow the […]
DHPA has submitted comments that propose ways to streamline the development and approval of Physician-Focused Payment Models (PFPMs) to the U.S. House Ways and Means Health Subcommittee’s Medicare Red Tape Relief Project. The new initiative is aimed at “delivering relief from the regulations and mandates that impede innovation, drive up costs, and ultimately stand in […]
DHPA has filed comments in response to CMS’s CY 2018 Updates to the Quality Payment Program (“QPP”) Proposed Rule. In its comment letter, DHPA provided three specific suggestions for CMS to consider incorporating into the Final Rule to ensure Medicare beneficiaries’ continued access to critically important drug treatments and to facilitate greater participation by independent […]